Faster & Better

As your most qualified world’s leading CDMO partner, Samsung Biologics delivers your success to IND & BLA Faster & Better with maximum flexibility.
We promise the Best.

Your molecule’s journey with Samsung Biologics’ Faster & Better CDO service.

Cell line development begins by the insertion of your gene of interest into an expression vector. The transfected cell expresses your target antibodies and the antibodies are secreted from the cells.

A large number of cell pools are then screened and single cell clones are isolated based on high titre and product quality. At the end of this process, the top 5 research cell banks are ranked and one is moved into process development.

During upstream process development, basal and feed media are optimised to ensure cell stability In bioreactors, pH, dissolved oxygen, temperature and other parameters are continuously optimised for the cell’s growth and viability to maximise production of your target protein.

Your target protein can be isolated through chromatography steps such as affinity and ion-exchange resin in downstream process. Impurities and viruses can be removed through chromatography and filter steps

In parallel with process development, optimal analytical conditions are set for your protein through size-exclusion chromatography, ELISA and more. A full spectrum of methods will be developed to evaluate purity, impurities, content and identification.

Buffers, surfactants and excipients are screened and combined to generate a stable liquid or lyophilized formulation for your target protein.

With the completion of the development process, your molecule moves into clinical production. Finally, the molecule is filled into vials ready for clinical trial.

As your most qualified world’s leading CDO, CMO, CRO partner, Samsung Biologics delivers your success to IND & BLA Faster & Better with maximum flexibility. We promise the Best.

Why Samsung Biologics CDO?

  • Contract Development Timeline
    • From Gene to IND in 12 months (Cell Line Development → Process Development → cGMP Manufacturing → IND Filing)
    • Accelerated Timelines (high productivity and stability)
  • Advanced Technology
    • Proprietary Cell Line, S-CHOice®
    • Proprietary Bispecific Platform, S-DUAL™
    • Systematic Developability Assessment, DEVELOPICK™
    • Expertise in development of various molecules
  • Excellent Quality
    • mAb titer of 11.6g/L, Bispecific titer of 4+g/L
    • Dedicated Project Management
    • Regulatory Filing Support
  • Tailored Support
    • Flexible CDO Service scope
    • Competitive & Variable Cost Structure
  • Seamless One-stop Service
    • Fully integrated development & manufacturing service
    • Global #1 manufacturing capacity



Your download is ready

Click Download.


Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.


Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.